Literature DB >> 26864202

Genomic characterization of sarcomatoid transformation in clear cell renal cell carcinoma.

Mark Bi1, Siming Zhao1, Jonathan W Said2, Maria J Merino3, Adebowale J Adeniran4, Zuoquan Xie5, Cayce B Nawaf5, Jaehyuk Choi6, Arie S Belldegrun7, Allan J Pantuck7, Harriet M Kluger8, Kaya Bilgüvar9, Richard P Lifton10, Brian Shuch11.   

Abstract

The presence of sarcomatoid features in clear cell renal cell carcinoma (ccRCC) confers a poor prognosis and is of unknown pathogenesis. We performed exome sequencing of matched normal-carcinomatous-sarcomatoid specimens from 21 subjects. Two tumors had hypermutation consistent with mismatch repair deficiency. In the remainder, sarcomatoid and carcinomatous elements shared 42% of somatic single-nucleotide variants (SSNVs). Sarcomatoid elements had a higher overall SSNV burden (mean 90 vs. 63 SSNVs, P = 4.0 × 10(-4)), increased frequency of nonsynonymous SSNVs in Pan-Cancer genes (mean 1.4 vs. 0.26, P = 0.002), and increased frequency of loss of heterozygosity (LOH) across the genome (median 913 vs. 460 Mb in LOH, P < 0.05), with significant recurrent LOH on chromosomes 1p, 9, 10, 14, 17p, 18, and 22. The most frequent SSNVs shared by carcinomatous and sarcomatoid elements were in known ccRCC genes including von Hippel-Lindau tumor suppressor (VHL), polybromo 1 (PBRM1), SET domain containing 2 (SETD2), phosphatase and tensin homolog (PTEN). Most interestingly, sarcomatoid elements acquired biallelic tumor protein p53 (TP53) mutations in 32% of tumors (P = 5.47 × 10(-17)); TP53 mutations were absent in carcinomatous elements in nonhypermutated tumors and rare in previously studied ccRCCs. Mutations in known cancer drivers AT-rich interaction domain 1A (ARID1A) and BRCA1 associated protein 1 (BAP1) were significantly mutated in sarcomatoid elements and were mutually exclusive with TP53 and each other. These findings provide evidence that sarcomatoid elements arise from dedifferentiation of carcinomatous ccRCCs and implicate specific genes in this process. These findings have implications for the treatment of patients with these poor-prognosis cancers.

Entities:  

Keywords:  dedifferentiation; kidney cancer; p53; sarcomatoid; transformation

Mesh:

Substances:

Year:  2016        PMID: 26864202      PMCID: PMC4776463          DOI: 10.1073/pnas.1525735113

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  60 in total

1.  Sarcomatoid renal cell carcinoma is an example of epithelial--mesenchymal transition.

Authors:  Joanna L Conant; Zhihua Peng; Mark F Evans; Shelly Naud; Kumarasen Cooper
Journal:  J Clin Pathol       Date:  2011-10-16       Impact factor: 3.411

2.  The somatic genomic landscape of chromophobe renal cell carcinoma.

Authors:  Caleb F Davis; Christopher J Ricketts; Min Wang; Lixing Yang; Andrew D Cherniack; Hui Shen; Christian Buhay; Hyojin Kang; Sang Cheol Kim; Catherine C Fahey; Kathryn E Hacker; Gyan Bhanot; Dmitry A Gordenin; Andy Chu; Preethi H Gunaratne; Michael Biehl; Sahil Seth; Benny A Kaipparettu; Christopher A Bristow; Lawrence A Donehower; Eric M Wallen; Angela B Smith; Satish K Tickoo; Pheroze Tamboli; Victor Reuter; Laura S Schmidt; James J Hsieh; Toni K Choueiri; A Ari Hakimi; Lynda Chin; Matthew Meyerson; Raju Kucherlapati; Woong-Yang Park; A Gordon Robertson; Peter W Laird; Elizabeth P Henske; David J Kwiatkowski; Peter J Park; Margaret Morgan; Brian Shuch; Donna Muzny; David A Wheeler; W Marston Linehan; Richard A Gibbs; W Kimryn Rathmell; Chad J Creighton
Journal:  Cancer Cell       Date:  2014-08-21       Impact factor: 31.743

3.  Sarcomatoid differentiation in renal cell carcinoma: a study of 101 cases.

Authors:  M de Peralta-Venturina; H Moch; M Amin; P Tamboli; S Hailemariam; M Mihatsch; J Javidan; H Stricker; J Y Ro; M B Amin
Journal:  Am J Surg Pathol       Date:  2001-03       Impact factor: 6.394

4.  RIF-1, a novel nuclear receptor corepressor that associates with the nuclear matrix.

Authors:  Hui Joyce Li; Zaffar K Haque; Amy Chen; Michael Mendelsohn
Journal:  J Cell Biochem       Date:  2007-11-01       Impact factor: 4.429

5.  Landscape of somatic single-nucleotide and copy-number mutations in uterine serous carcinoma.

Authors:  Siming Zhao; Murim Choi; John D Overton; Stefania Bellone; Dana M Roque; Emiliano Cocco; Federica Guzzo; Diana P English; Joyce Varughese; Sara Gasparrini; Ileana Bortolomai; Natalia Buza; Pei Hui; Maysa Abu-Khalaf; Antonella Ravaggi; Eliana Bignotti; Elisabetta Bandiera; Chiara Romani; Paola Todeschini; Renata Tassi; Laura Zanotti; Luisa Carrara; Sergio Pecorelli; Dan-Arin Silasi; Elena Ratner; Masoud Azodi; Peter E Schwartz; Thomas J Rutherford; Amy L Stiegler; Shrikant Mane; Titus J Boggon; Joseph Schlessinger; Richard P Lifton; Alessandro D Santin
Journal:  Proc Natl Acad Sci U S A       Date:  2013-01-28       Impact factor: 11.205

6.  HIF-alpha effects on c-Myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinoma.

Authors:  John D Gordan; Priti Lal; Vijay R Dondeti; Richard Letrero; Krishna N Parekh; C Elisa Oquendo; Roger A Greenberg; Keith T Flaherty; W Kimryn Rathmell; Brian Keith; M Celeste Simon; Katherine L Nathanson
Journal:  Cancer Cell       Date:  2008-12-09       Impact factor: 31.743

7.  BAP1 loss defines a new class of renal cell carcinoma.

Authors:  Samuel Peña-Llopis; Silvia Vega-Rubín-de-Celis; Arnold Liao; Nan Leng; Andrea Pavía-Jiménez; Shanshan Wang; Toshinari Yamasaki; Leah Zhrebker; Sharanya Sivanand; Patrick Spence; Lisa Kinch; Tina Hambuch; Suneer Jain; Yair Lotan; Vitaly Margulis; Arthur I Sagalowsky; Pia Banerji Summerour; Wareef Kabbani; S W Wendy Wong; Nick Grishin; Marc Laurent; Xian-Jin Xie; Christian D Haudenschild; Mark T Ross; David R Bentley; Payal Kapur; James Brugarolas
Journal:  Nat Genet       Date:  2012-06-10       Impact factor: 38.330

8.  An integrated map of genetic variation from 1,092 human genomes.

Authors:  Goncalo R Abecasis; Adam Auton; Lisa D Brooks; Mark A DePristo; Richard M Durbin; Robert E Handsaker; Hyun Min Kang; Gabor T Marth; Gil A McVean
Journal:  Nature       Date:  2012-11-01       Impact factor: 49.962

9.  The FAT epidemic: a gene family frequently mutated across multiple human cancer types.

Authors:  Luc G T Morris; Deepa Ramaswami; Timothy A Chan
Journal:  Cell Cycle       Date:  2013-03-14       Impact factor: 4.534

10.  Recurrent activating mutation in PRKACA in cortisol-producing adrenal tumors.

Authors:  Gerald Goh; Ute I Scholl; James M Healy; Murim Choi; Manju L Prasad; Carol Nelson-Williams; John W Kunstman; John W Kuntsman; Reju Korah; Anna-Carinna Suttorp; Dimo Dietrich; Matthias Haase; Holger S Willenberg; Peter Stålberg; Per Hellman; Göran Akerström; Peyman Björklund; Tobias Carling; Richard P Lifton
Journal:  Nat Genet       Date:  2014-04-20       Impact factor: 38.330

View more
  39 in total

1.  A multicenter, prospective phase II trial of gemcitabine plus axitinib in patients with renal cell carcinoma with a predominant sarcomatoid component.

Authors:  Inkeun Park; Hyo Jin Lee; Woo Kyoon Bae; Shinkyo Yoon; Jae Lyun Lee
Journal:  Invest New Drugs       Date:  2019-06-24       Impact factor: 3.850

2.  Sarcomatoid Renal Cell Carcinoma Has a Distinct Molecular Pathogenesis, Driver Mutation Profile, and Transcriptional Landscape.

Authors:  Zixing Wang; Tae Beom Kim; Bo Peng; Jose Karam; Chad Creighton; Aron Joon; Fumi Kawakami; Patricia Trevisan; Eric Jonasch; Chi-Wan Chow; Jaime Rodriguez Canales; Pheroze Tamboli; Nizar Tannir; Christopher Wood; Federico Monzon; Keith Baggerly; Marileila Varella-Garcia; Bogdan Czerniak; Ignacio Wistuba; Gordon Mills; Kenna Shaw; Ken Chen; Kanishka Sircar
Journal:  Clin Cancer Res       Date:  2017-07-14       Impact factor: 12.531

Review 3.  Epidemiology, biology and treatment of sarcomatoid RCC: current state of the art.

Authors:  Cedric Lebacle; Aydin Pooli; Thomas Bessede; Jacques Irani; Allan J Pantuck; Alexandra Drakaki
Journal:  World J Urol       Date:  2018-06-01       Impact factor: 4.226

4.  Transcriptomic Profiling of the Tumor Microenvironment Reveals Distinct Subgroups of Clear Cell Renal Cell Cancer: Data from a Randomized Phase III Trial.

Authors:  A Ari Hakimi; Martin H Voss; Fengshen Kuo; Alejandro Sanchez; Ming Liu; Briana G Nixon; Lynda Vuong; Irina Ostrovnaya; Ying-Bei Chen; Victor Reuter; Nadeem Riaz; Yuan Cheng; Parul Patel; Mahtab Marker; Albert Reising; Ming O Li; Timothy A Chan; Robert J Motzer
Journal:  Cancer Discov       Date:  2019-01-08       Impact factor: 39.397

5.  A randomized phase 2 study of MK-2206 versus everolimus in refractory renal cell carcinoma.

Authors:  E Jonasch; E Hasanov; P G Corn; T Moss; K R Shaw; S Stovall; V Marcott; B Gan; S Bird; X Wang; K A Do; P F Altamirano; A J Zurita; L A Doyle; P N Lara; N M Tannir
Journal:  Ann Oncol       Date:  2017-04-01       Impact factor: 32.976

6.  Integration of Recurrent Somatic Mutations with Clinical Outcomes: A Pooled Analysis of 1049 Patients with Clear Cell Renal Cell Carcinoma.

Authors:  Brandon John Manley; Emily C Zabor; Jozefina Casuscelli; Daniel M Tennenbaum; Almedina Redzematovic; Maria F Becerra; Nicole Benfante; Yusuke Sato; Teppei Morikawa; Haruki Kume; Masashi Fukayama; Yukio Homma; Seishi Ogawa; Maria E Arcila; Martin H Voss; Darren R Feldman; Jonathan A Coleman; Victor E Reuter; Robert J Motzer; Paul Russo; James J Hsieh; A Ari Hakimi
Journal:  Eur Urol Focus       Date:  2016-07-16

Review 7.  Evolving Treatment Paradigms in Non-clear Cell Kidney Cancer.

Authors:  Ulka Vaishampayan
Journal:  Curr Treat Options Oncol       Date:  2018-01-24

Review 8.  Precision medicine from the renal cancer genome.

Authors:  Yasser Riazalhosseini; Mark Lathrop
Journal:  Nat Rev Nephrol       Date:  2016-10-03       Impact factor: 28.314

Review 9.  Molecular profiling of renal cell carcinoma: building a bridge toward clinical impact.

Authors:  Brandon J Manley; Abraham Ari Hakimi
Journal:  Curr Opin Urol       Date:  2016-09       Impact factor: 2.309

10.  High fidelity of driver chromosomal alterations among primary and metastatic renal cell carcinomas: implications for tumor clonal evolution and treatment.

Authors:  Eril J Kouba; John N Eble; Novae Simper; David J Grignon; Mingsheng Wang; Shaobo Zhang; Lisha Wang; Guido Martignoni; Sean R Williamson; Matteo Brunelli; Claudio Luchini; Anna Calió; Liang Cheng
Journal:  Mod Pathol       Date:  2016-07-29       Impact factor: 7.842

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.